Home > FDA MedWatch > FDA MedWatch – Tumor Necrosis Factor (TNF) blockers: UPDATE

FDA MedWatch – Tumor Necrosis Factor (TNF) blockers: UPDATE

[UPDATED 11/04/2011] Healthcare professionals should remain vigilant for cases of malignancy in patients treated with TNF blockers, and report such cases to MedWatch. The reports should include:

• patient characteristics (age, gender, no patient identifiers)
• risk factors for malignancy
• exposure to other immune suppressing products or products with risk of malignancy
• indication for TNF blocker treatment
• TNF blocker exposure (duration, dose)
• cancer diagnosis (date of diagnosis, stage)
• biopsy results
• outcomes of malignancy (treatments, event outcome)

CLICK HERE to read the MedWatch safety alert, including a link to the Drug Safety Communication.

Advertisements
  1. No comments yet.
  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

%d bloggers like this: